Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarte

PALM BEACH, Fla., May 8, 2025 /PRNewswire/ -- Exec Edge announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes Fold Holdings, Inc (NASDAQ:FLD), Climb Bio Inc. (NASDAQ:CLYM), Rex American Resources Corp. (NYSE:REX), The ONE Group Hospitality, Inc. (NASDAQ:STKS) and Aurora Cannabis Inc. (NASDAQ:ACB). Our reports dive deep into

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025. 24th Annual Needham Virtual Healthcare Conference Format: Presentation and one-on-one investor meetingsDate: April 10, 2025Time: 8:45 a.m. ETWebcast: Click here About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a br

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position Expanded Pipeline to Include CLYM116, an Anti-APRIL (A PRoliferation-Inducing Ligand) Monoclonal Antibody for Treatment of IgA Nephropathy (IgAN) Appointed Perrin Wilson, Ph.D. as Chief Business Officer Ended 2024 in a Strong Financial Position, with Cash Runway Expected Through 202

WELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed below. TD Cowen 45th Annual Health Care Conference Format: Formal presentation and one-on-one investor meetingsDate: March 4, 2025Time: 9:50 a.m. ETWebcast: Click here Leerink's Global Healthcare Conference 2025Format: Fireside chat and one-on-one investor meetings Date: March 10, 2025Time: 10:00 a.m. ETWebcast: Click here About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's pipeline inc

WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry. "I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team," said Aoife Brennan, President and CEO of Climb Bio. "Perrin brings extensive experience and a track record of success across large pharma and biotech to Climb Bio. As Chief Business Officer, she will lead the Company's pre-commercial planning, communications, and business development efforts. Perrin's proven expertise in negotiat

WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually February 11-12, 2025. Oppenheimer 35th Annual Healthcare Life Sciences Conference Format: Presentation and one-on-one investor meetingsDate: February 12, 2025Time: 9:20 a.m. ETWebcast: Click here About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depleti

Transaction Expands Climb Bio's Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs Preclinical Data Expected to be Shared Later in 2025 WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070, Mabworks) for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody, in the territory outside of Greater China

WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (NASDAQ:CLYM) today announced that the company will be added to the NASDAQ Biotech Index (NASDAQ:NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio's inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a mo

Leerink Partners initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

10-Q - Climb Bio, Inc. (0001768446) (Filer)

8-K - Climb Bio, Inc. (0001768446) (Filer)

DEFA14A - Climb Bio, Inc. (0001768446) (Filer)

DEF 14A - Climb Bio, Inc. (0001768446) (Filer)

S-8 - Climb Bio, Inc. (0001768446) (Filer)

8-K - Climb Bio, Inc. (0001768446) (Filer)

8-K - Climb Bio, Inc. (0001768446) (Filer)

424B5 - Climb Bio, Inc. (0001768446) (Filer)

10-K - Climb Bio, Inc. (0001768446) (Filer)

SCHEDULE 13G/A - Climb Bio, Inc. (0001768446) (Subject)

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry. "I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team," said Aoife Brennan, President and CEO of Climb Bio. "Perrin brings extensive experience and a track record of success across large pharma and biotech to Climb Bio. As Chief Business Officer, she will lead the Company's pre-commercial planning, communications, and business development efforts. Perrin's proven expertise in negotiat

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® a

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

3 - Climb Bio, Inc. (0001768446) (Issuer)

3 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)